AbCellera Biologics Inc. (ABCL)
2.43
-0.01 (-0.41%)
At close: Apr 15, 2025, 3:59 PM
2.44
0.41%
After-hours: Apr 15, 2025, 06:20 PM EDT
-0.41% (1D)
| Bid | 2.37 |
| Market Cap | 724.11M |
| Revenue (ttm) | 28.83M |
| Net Income (ttm) | -162.86M |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -4.42 |
| Forward PE | -4.89 |
| Analyst | Buy |
| Ask | 2.5 |
| Volume | 5,654,710 |
| Avg. Volume (20D) | 4,684,299 |
| Open | 2.42 |
| Previous Close | 2.44 |
| Day's Range | 2.34 - 2.50 |
| 52-Week Range | 1.89 - 4.34 |
| Beta | 0.49 |
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 596
Stock Exchange NASDAQ
Ticker Symbol ABCL
Website https://www.abcellera.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 188.07% from the latest price.
Stock ForecastsNext Earnings Release
AbCellera Biologics Inc. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
+15.94%
Shares of healthcare technology stocks are trading...
Unlock content with
Pro Subscription
1 month ago
-11.3%
AbCellera Biologics shares are trading lower after the company reported worse-than-expected Q4 sales results. Also, Stifel cut its price target on the stock from $12 to $10.
